Xiaolin Liu

Xiaolin Liu

Auto-generated profile, based on publicly available information

Xiaolin Liu

Max Planck Institute for Evolutionary Biology, August-Thienemann-Str. 2, 24306 Plön, Germany; Section of Evolutionary Medicine, Institute for Experimental Medicine, Kiel University, Arnold-Heller-Str. 3, 24105 Kiel, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
LCLiang Chen
Liang Chen
NZNa Zhao
Na Zhao
JCJiabao Cao
Jiabao Cao
XLXiaolin Liu
Xiaolin Liu
JXJiayue Xu
Jiayue Xu
JWJun Wang
Jun Wang
In-depth profiling of genetic variations in the gut microbiome is highly desired for understanding its functionality and impacts on host health and disease. Here, by harnessing the long read advantage provided by Oxford Nanopore Technology (ONT), we characterize fine-scale genetic variations of structural variations (SVs) in hundreds of gut microbiomes from healthy humans. ONT long reads dramatically improve the quality of metagenomic assemblies, enable reliable detection of a large, expanded set of structural variation types (notably including large insertions and inversions). We find SVs are highly distinct between individuals and stable within an individual, representing gut microbiome fingerprints that shape strain-level differentiations in function within species, complicating the associations to metabolites and host phenotypes such as blood glucose. In summary, our study strongly emphasizes that incorporating ONT reads into metagenomic analyses expands the detection scope of genetic variations, enables profiling strain-level variations in gut microbiome, and their intricate correlations with metabolome.

17 April 2023 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
QWQian Wang
Qian Wang
CYChenchen Yang
Chenchen Yang
LYLi Yin
Li Yin
JSJing Sun
Jing Sun
WWwei wang
wei wang
NZNanshan Zhong
Nanshan Zhong
The highly contagious SARS-CoV-2 Omicron subvariants severely attenuated the effectiveness of currently licensed SARS-CoV-2 vaccines based on ancestral strains administered via intramuscular injection. In this study, we generated a recombinant, replication-incompetent human adenovirus type 5, Ad5-S-Omicron, that expresses Omicron BA.1 spike. Intranasal, but not intramuscular vaccination, elicited spike-specific respiratory mucosal IgA and residential T cell immune responses, in addition to systemic neutralizing antibodies and T cell immune responses against most Omicron subvariants. We tested intranasal Ad5-S-Omicron as a heterologous booster in mice that previously received intramuscular injection of inactivated ancestral vaccine. In addition to inducing serum broadly neutralizing antibodies, there was a significant induction of respiratory mucosal IgA and neutralizing activities against Omicron subvariants BA.1, BA.2, BA.5, BA.2.75, BF.7 as well as pre-Omicron strains Wildtype, Beta, and Delta. Serum and mucosal neutralizing activities against recently emerged XBB, BQ.1, and BQ.1.1 could also be detected but were much lower. Nasal lavage fluids from intranasal vaccination contained multimeric IgA that can bind to at least 10 spike proteins, including Omicron subvariants and pre-Omicron strains, and possessed broadly neutralizing activities. Intranasal vaccination using Ad5-S-Omicron or instillation of intranasal vaccinee’s nasal lavage fluids in mouse nostrils protected mice against Omicron challenge. Taken together, intranasal Ad5-S-Omicron booster on the basis of ancestral vaccines can establish effective mucosal and systemic immunity against Omicron subvariants and multiple SARS-CoV-2 variants. This candidate vaccine warrants further development as a safe, effective, and user-friendly infection and transmission-blocking vaccine.

8 June 2016 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
MYMeiling Yu
Meiling Yu
JQJianghua Qian
Jianghua Qian
DGDaohua Guo
Daohua Guo
LLLi Li
Li Li
XLXiaolin Liu
Xiaolin Liu
A 61-year-old female patient was admitted to hospital following development of a whole-body rash for 10 days, diarrhea for 7 days, and unconsciousness and oliguria for 1 day. The patient had developed stomach discomfort following the oral administration of non‑steroidal anti‑inflammatory drugs, the exact nature of which was unknown, for the treatment of arthritic pain for >1 month. The patient was then prescribed omeprazole enteric‑coated tablets (20 mg twice daily) for treatment of this symptom. However, the patient developed a whole‑body rash 7 days after administering omeprazole, 10 days prior to admission. This symptom was followed by severe diarrhea with nausea and vomiting after 10 days, then shock. The shock occurred after administering omeprazole for 16 days. The patient developed a whole body rash 7 days after administering omeprazole, then 3 days later (after administering omeprazole for 10 days) severe diarrhea with nausea and vomiting occurred. The shock remained until administering omeprazole on the 16th day, with severe diarrhea with nausea and vomiting occurring 6 days later. The patient's condition did not improve following treatment for allergies, low blood pressure and oliguria in the Intensive Care Unit (ICU) department at Suzhou Municipal Hospital. For further diagnosis and treatment, the patient was admitted to the ICU department of The First Affiliated Hospital of Bengbu Medical College and was given a fluid infusion, antibiotics and phlegm‑reducing treatment, a plasma infusion, blood filtration, and anti‑diarrheal and anti‑allergy treatment. The patient's vital signs were stable, with a normal temperature and hemogram results, and improved kidney function and deflorescence. Genetic screening revealed that the patient poorly metabolized omeprazole. Therefore, severe adverse reactions (allergic shock, rash and diarrhea) experienced by the patient were caused by the accumulation of omeprazole metabolites resulting from its slow metabolism in vivo.

23 October 2026 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
XLXiaolin Liu
Xiaolin Liu
SPSabrina Patzelt
Sabrina Patzelt
YMYue Ma
Yue Ma
ACAleksa Cepic
Aleksa Cepic
HDHasan Onur Dikmen
Hasan Onur Dikmen
JBJohn F. Baines
John F. Baines
Pemphigoid diseases (PD) are autoimmune blistering disorders in which alterations of the skin and gut microbiota have been reported, yet how microbial variation relates to disease severity remains unclear. Using a bullous pemphigoid-like mouse model, we compared genetically identical C57BL/6J mice from two breeding facilities that differed in their baseline microbiota. Mice from Charles River developed markedly milder disease than in-house-bred animals. Co-housing partially homogenized their gut microbiota, shifting in-house mice asymmetrically toward the Charles River community, coinciding with reduced disease severity in co-housed in-house mice. The skin microbiota showed more modest and less consistent shifts, potentially reflecting its lower biomass and higher technical noise. Lower gut microbial diversity and enrichment of pro-inflammatory taxa like Turicimonas muris and Muribaculum intestinale were linked to more severe disease, whereas taxa such as Lactobacillus intestinalis and Parabacteroides distasonis correlated with protection. A gut taxon belonging to Scatocola was identified as a candidate negative predictor of disease severity in correlation and machine-learning analyses. Together, these findings support an association between natural variation in the gut microbiota and autoimmune skin inflammation and identify candidate microbial taxa that warrant further functional validation.

1 October 2025 in bioRxiv
Verified
Preprint
Open access
XLXiaolin Liu
Xiaolin Liu
SPSabrina Patzelt
Sabrina Patzelt
YMYue Ma
Yue Ma
ACAleksa Cepic
Aleksa Cepic
HDHasan-Onur Dikmen
Hasan-Onur Dikmen
JBJohn F. Baines
John F. Baines
Pemphigoid diseases (PD) are autoimmune blistering diseases with reported alterations in skin and gut microbiota, though their causal contribution to disease pathophysiology remains unclear. Using a passive model of bullous pemphigoid-like epidermolysis bullosa acquisita (BP-like EBA), we compared C57BL/6J mice from two sources (in-house vs. Charles River) that differed in their baseline microbiota. Charles River mice developed significantly less severe disease. Co-housing led to partial homogenization of the gut microbiota, driven by asymmetric transfer of taxa from Charles River to in-house mice, which corresponded with reduced disease severity in the latter. The skin microbiota, however, showed limited exchange. Disease severity was inversely associated with gut microbial alpha diversity, with protective taxa such as Lactobacillus intestinalis and Parabacteroides distasonis enriched in Charles River mice, while pro-inflammatory taxa including Turicimonas muris and Muribaculum intestinale were enriched in in-house mice. A machine learning model further identified a gut taxon most closely matching the candidate genus Scatocola as a strong negative predictor of disease severity. Through experimental exposure and uptake of variable gut microbiota, these findings suggest a direct role of gut microbiota in mediating the severity of the experimental BP-like EBA and highlight the potential of microbiota-based strategies for therapeutic intervention in PD.